A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma

A gynecologic oncology group study

Agustin A. Garcia, Michael W. Sill, Heather A. Lankes, Andrew K. Godwin, Robert S. Mannel, Deborah Kay Armstrong, Robert L. Carolla, Marcia K. Liepman, Nick M. Spirtos, Edgar G. Fischer, Kimberly K. Leslie

Research output: Contribution to journalArticle

Abstract

Objective: Activation and dimerization of the ERBB family play a role in the pathogenesis and progression of ovarian cancer. We conducted a phase II trial to evaluate the activity and tolerability of lapatinib in patients with recurrent or persistent epithelial ovarian cancer (EOC) and to explore the clinical value of expression levels of epidermal growth factor receptors (EGFR), phosphorylated EGFR, HER-2/neu, and Ki-67, and the presence of EGFR mutations. Methods: Eligible patients had recurrent or persistent EOC or primary peritoneal carcinoma, measurable disease, and up to 2 prior chemotherapy regimens for recurrent disease. Patients were treated with lapatinib 1500 mg/day. The primary endpoint of efficacy was 6-month progression free survival (PFS). Results: Twenty-five of 28 patients were eligible and evaluable for analysis of efficacy and toxicity. Two (8.0%) were alive and progression-free at 6 months. No objective responses were observed. There were 1 grade 4 toxicity (fatigue) and few grade 3 toxicities. Associations between Ki-67 with prior platinum-free interval, PFS, and a polymorphism in EGFR were suggested. Conclusions: Lapatinib has minimal activity in recurrent ovarian cancer. Ki-67 expression may be associated with prior PFS and a polymorphism in EGFR exon 20 (2361G>A, Q787Q).

Original languageEnglish (US)
Pages (from-to)569-574
Number of pages6
JournalGynecologic Oncology
Volume124
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Carcinoma
Disease-Free Survival
Ovarian Neoplasms
Therapeutics
Dimerization
Platinum
Fatigue
Exons
ErbB Receptors
lapatinib
Drug Therapy
Mutation
Ovarian epithelial cancer

Keywords

  • Epidermal growth factor receptor (EGFR)
  • Ki-67
  • Lapatinib
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma : A gynecologic oncology group study. / Garcia, Agustin A.; Sill, Michael W.; Lankes, Heather A.; Godwin, Andrew K.; Mannel, Robert S.; Armstrong, Deborah Kay; Carolla, Robert L.; Liepman, Marcia K.; Spirtos, Nick M.; Fischer, Edgar G.; Leslie, Kimberly K.

In: Gynecologic Oncology, Vol. 124, No. 3, 03.2012, p. 569-574.

Research output: Contribution to journalArticle

Garcia, AA, Sill, MW, Lankes, HA, Godwin, AK, Mannel, RS, Armstrong, DK, Carolla, RL, Liepman, MK, Spirtos, NM, Fischer, EG & Leslie, KK 2012, 'A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study', Gynecologic Oncology, vol. 124, no. 3, pp. 569-574. https://doi.org/10.1016/j.ygyno.2011.10.022
Garcia, Agustin A. ; Sill, Michael W. ; Lankes, Heather A. ; Godwin, Andrew K. ; Mannel, Robert S. ; Armstrong, Deborah Kay ; Carolla, Robert L. ; Liepman, Marcia K. ; Spirtos, Nick M. ; Fischer, Edgar G. ; Leslie, Kimberly K. / A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma : A gynecologic oncology group study. In: Gynecologic Oncology. 2012 ; Vol. 124, No. 3. pp. 569-574.
@article{d648d727eb924dbdaabe9d0ce2be906c,
title = "A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study",
abstract = "Objective: Activation and dimerization of the ERBB family play a role in the pathogenesis and progression of ovarian cancer. We conducted a phase II trial to evaluate the activity and tolerability of lapatinib in patients with recurrent or persistent epithelial ovarian cancer (EOC) and to explore the clinical value of expression levels of epidermal growth factor receptors (EGFR), phosphorylated EGFR, HER-2/neu, and Ki-67, and the presence of EGFR mutations. Methods: Eligible patients had recurrent or persistent EOC or primary peritoneal carcinoma, measurable disease, and up to 2 prior chemotherapy regimens for recurrent disease. Patients were treated with lapatinib 1500 mg/day. The primary endpoint of efficacy was 6-month progression free survival (PFS). Results: Twenty-five of 28 patients were eligible and evaluable for analysis of efficacy and toxicity. Two (8.0{\%}) were alive and progression-free at 6 months. No objective responses were observed. There were 1 grade 4 toxicity (fatigue) and few grade 3 toxicities. Associations between Ki-67 with prior platinum-free interval, PFS, and a polymorphism in EGFR were suggested. Conclusions: Lapatinib has minimal activity in recurrent ovarian cancer. Ki-67 expression may be associated with prior PFS and a polymorphism in EGFR exon 20 (2361G>A, Q787Q).",
keywords = "Epidermal growth factor receptor (EGFR), Ki-67, Lapatinib, Ovarian cancer",
author = "Garcia, {Agustin A.} and Sill, {Michael W.} and Lankes, {Heather A.} and Godwin, {Andrew K.} and Mannel, {Robert S.} and Armstrong, {Deborah Kay} and Carolla, {Robert L.} and Liepman, {Marcia K.} and Spirtos, {Nick M.} and Fischer, {Edgar G.} and Leslie, {Kimberly K.}",
year = "2012",
month = "3",
doi = "10.1016/j.ygyno.2011.10.022",
language = "English (US)",
volume = "124",
pages = "569--574",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma

T2 - A gynecologic oncology group study

AU - Garcia, Agustin A.

AU - Sill, Michael W.

AU - Lankes, Heather A.

AU - Godwin, Andrew K.

AU - Mannel, Robert S.

AU - Armstrong, Deborah Kay

AU - Carolla, Robert L.

AU - Liepman, Marcia K.

AU - Spirtos, Nick M.

AU - Fischer, Edgar G.

AU - Leslie, Kimberly K.

PY - 2012/3

Y1 - 2012/3

N2 - Objective: Activation and dimerization of the ERBB family play a role in the pathogenesis and progression of ovarian cancer. We conducted a phase II trial to evaluate the activity and tolerability of lapatinib in patients with recurrent or persistent epithelial ovarian cancer (EOC) and to explore the clinical value of expression levels of epidermal growth factor receptors (EGFR), phosphorylated EGFR, HER-2/neu, and Ki-67, and the presence of EGFR mutations. Methods: Eligible patients had recurrent or persistent EOC or primary peritoneal carcinoma, measurable disease, and up to 2 prior chemotherapy regimens for recurrent disease. Patients were treated with lapatinib 1500 mg/day. The primary endpoint of efficacy was 6-month progression free survival (PFS). Results: Twenty-five of 28 patients were eligible and evaluable for analysis of efficacy and toxicity. Two (8.0%) were alive and progression-free at 6 months. No objective responses were observed. There were 1 grade 4 toxicity (fatigue) and few grade 3 toxicities. Associations between Ki-67 with prior platinum-free interval, PFS, and a polymorphism in EGFR were suggested. Conclusions: Lapatinib has minimal activity in recurrent ovarian cancer. Ki-67 expression may be associated with prior PFS and a polymorphism in EGFR exon 20 (2361G>A, Q787Q).

AB - Objective: Activation and dimerization of the ERBB family play a role in the pathogenesis and progression of ovarian cancer. We conducted a phase II trial to evaluate the activity and tolerability of lapatinib in patients with recurrent or persistent epithelial ovarian cancer (EOC) and to explore the clinical value of expression levels of epidermal growth factor receptors (EGFR), phosphorylated EGFR, HER-2/neu, and Ki-67, and the presence of EGFR mutations. Methods: Eligible patients had recurrent or persistent EOC or primary peritoneal carcinoma, measurable disease, and up to 2 prior chemotherapy regimens for recurrent disease. Patients were treated with lapatinib 1500 mg/day. The primary endpoint of efficacy was 6-month progression free survival (PFS). Results: Twenty-five of 28 patients were eligible and evaluable for analysis of efficacy and toxicity. Two (8.0%) were alive and progression-free at 6 months. No objective responses were observed. There were 1 grade 4 toxicity (fatigue) and few grade 3 toxicities. Associations between Ki-67 with prior platinum-free interval, PFS, and a polymorphism in EGFR were suggested. Conclusions: Lapatinib has minimal activity in recurrent ovarian cancer. Ki-67 expression may be associated with prior PFS and a polymorphism in EGFR exon 20 (2361G>A, Q787Q).

KW - Epidermal growth factor receptor (EGFR)

KW - Ki-67

KW - Lapatinib

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84856702658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856702658&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.10.022

DO - 10.1016/j.ygyno.2011.10.022

M3 - Article

VL - 124

SP - 569

EP - 574

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -